Jagsonpal Historical Income Statement

JAGSNPHARM

636.65 9.80 1.52%

Historical analysis of Jagsonpal Pharmaceuticals income statement accounts such as Total Revenue of 1.8 B or Gross Profit of 941.8 M can show how well Jagsonpal Pharmaceuticals Limited performed in making a profits. Evaluating Jagsonpal Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Jagsonpal Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Jagsonpal Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jagsonpal Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Jagsonpal Income Statement Analysis

Jagsonpal Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jagsonpal Pharmaceuticals shareholders. The income statement also shows Jagsonpal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Jagsonpal Pharmaceuticals Income Statement Chart

As of now, Jagsonpal Pharmaceuticals' Total Other Income Expense Net is increasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Net Income is estimated to increase to about 235.9 M, while Depreciation And Amortization is projected to decrease to under 14.6 M.

Depreciation And Amortization Interest Expense Total Revenue Gross Profit Other Operating Expenses Net Income Applicable To Common Shares

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Jagsonpal Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Jagsonpal Pharmaceuticals Limited minus its cost of goods sold. It is profit before Jagsonpal Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Jagsonpal Pharmaceuticals. It is also known as Jagsonpal Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Jagsonpal Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Jagsonpal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Interest Expense	2.6M	4.1M	8.1M	7.7M
Depreciation And Amortization	15.3M	11.8M	16.6M	14.6M

Interest Expense Depreciation And Amortization

Jagsonpal Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Research Development	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.81	-0.26	-0.26	-0.35	-0.17	-0.05	0.02	-0.1	-0.34	-0.22	-0.47	-0.18	-0.33	0.25	-0.58	0.58	-0.21	-0.35	0.87	-0.8	-0.19
Interest Expense	0.81		-0.51	-0.54	-0.6	-0.45	-0.34	-0.29	-0.19	-0.56	-0.52	-0.71	-0.5	-0.57	0.05	-0.85	0.78	-0.53	-0.64	0.97	-0.86	-0.46
Total Revenue	-0.26	-0.51		0.74	0.99	0.9	0.89	0.87	0.69	0.44	0.88	0.36	0.86	0.9	-0.21	0.52	-0.24	0.84	0.91	-0.53	0.36	0.69
Gross Profit	-0.26	-0.54	0.74		0.73	0.74	0.62	0.6	0.03	0.91	0.64	0.21	0.64	0.59	-0.05	0.55	-0.34	0.63	0.65	-0.47	0.46	0.21
Other Operating Expenses	-0.35	-0.6	0.99	0.73		0.85	0.82	0.8	0.68	0.47	0.84	0.41	0.81	0.89	-0.23	0.54	-0.28	0.8	0.9	-0.62	0.43	0.71
Operating Income	-0.17	-0.45	0.9	0.74	0.85		0.98	0.97	0.55	0.44	0.92	0.48	0.92	0.86	0.09	0.56	-0.21	0.91	0.91	-0.45	0.25	0.56
Ebit	-0.05	-0.34	0.89	0.62	0.82	0.98		1.0	0.65	0.28	0.92	0.45	0.93	0.85	0.07	0.48	-0.13	0.91	0.89	-0.36	0.15	0.62
Ebitda	0.02	-0.29	0.87	0.6	0.8	0.97	1.0		0.65	0.25	0.91	0.42	0.92	0.84	0.09	0.44	-0.09	0.9	0.87	-0.3	0.09	0.61
Cost Of Revenue	-0.1	-0.19	0.69	0.03	0.68	0.55	0.65	0.65		-0.32	0.62	0.3	0.59	0.69	-0.25	0.18	0.01	0.57	0.66	-0.29	0.04	0.79
Total Operating Expenses	-0.34	-0.56	0.44	0.91	0.47	0.44	0.28	0.25	-0.32		0.34	0.17	0.34	0.32	0.0	0.49	-0.37	0.35	0.38	-0.46	0.51	-0.03
Income Before Tax	-0.22	-0.52	0.88	0.64	0.84	0.92	0.92	0.91	0.62	0.34		0.64	1.0	0.96	0.05	0.59	-0.29	0.99	0.9	-0.55	0.3	0.71
Total Other Income Expense Net	-0.47	-0.71	0.36	0.21	0.41	0.48	0.45	0.42	0.3	0.17	0.64		0.64	0.62	0.34	0.63	-0.42	0.66	0.58	-0.71	0.41	0.56
Net Income	-0.18	-0.5	0.86	0.64	0.81	0.92	0.93	0.92	0.59	0.34	1.0	0.64		0.93	0.07	0.58	-0.29	0.99	0.88	-0.52	0.29	0.66
Income Tax Expense	-0.33	-0.57	0.9	0.59	0.89	0.86	0.85	0.84	0.69	0.32	0.96	0.62	0.93		-0.04	0.58	-0.28	0.93	0.93	-0.61	0.33	0.79
Selling General Administrative	0.25	0.05	-0.21	-0.05	-0.23	0.09	0.07	0.09	-0.25	0.0	0.05	0.34	0.07	-0.04		0.15	0.0	0.09	0.03	0.15	-0.33	-0.06
Selling And Marketing Expenses	-0.58	-0.85	0.52	0.55	0.54	0.56	0.48	0.44	0.18	0.49	0.59	0.63	0.58	0.58	0.15		-0.84	0.63	0.7	-0.8	0.76	0.51
Research Development	0.58	0.78	-0.24	-0.34	-0.28	-0.21	-0.13	-0.09	0.01	-0.37	-0.29	-0.42	-0.29	-0.28	0.0	-0.84		-0.35	-0.38	0.74	-0.84	-0.29
Net Income From Continuing Ops	-0.21	-0.53	0.84	0.63	0.8	0.91	0.91	0.9	0.57	0.35	0.99	0.66	0.99	0.93	0.09	0.63	-0.35		0.9	-0.55	0.32	0.68
Tax Provision	-0.35	-0.64	0.91	0.65	0.9	0.91	0.89	0.87	0.66	0.38	0.9	0.58	0.88	0.93	0.03	0.7	-0.38	0.9		-0.65	0.4	0.78
Interest Income	0.87	0.97	-0.53	-0.47	-0.62	-0.45	-0.36	-0.3	-0.29	-0.46	-0.55	-0.71	-0.52	-0.61	0.15	-0.8	0.74	-0.55	-0.65		-0.87	-0.51
Net Interest Income	-0.8	-0.86	0.36	0.46	0.43	0.25	0.15	0.09	0.04	0.51	0.3	0.41	0.29	0.33	-0.33	0.76	-0.84	0.32	0.4	-0.87		0.29
Reconciled Depreciation	-0.19	-0.46	0.69	0.21	0.71	0.56	0.62	0.61	0.79	-0.03	0.71	0.56	0.66	0.79	-0.06	0.51	-0.29	0.68	0.78	-0.51	0.29

Click cells to compare fundamentals

Jagsonpal Pharmaceuticals Account Relationship Matchups

Jagsonpal Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	11.3M	10.9M	15.3M	11.8M	16.6M	14.6M
Interest Expense	3.8M	4.3M	2.6M	4.1M	8.1M	7.7M
Total Revenue	1.6B	1.9B	2.3B	2.4B	2.1B	1.8B
Gross Profit	1.0B	1.1B	1.3B	1.4B	652.6M	941.8M
Other Operating Expenses	1.5B	1.7B	2.0B	2.0B	1.9B	1.7B
Operating Income	74.0M	187.9M	239.9M	338.9M	214.0M	111.4M
Ebit	99.3M	223.9M	269.3M	352.2M	306.8M	154.4M
Ebitda	110.6M	234.7M	284.5M	364.0M	323.5M	174.5M
Cost Of Revenue	562.3M	809.3M	961.1M	931.0M	1.4B	876.7M
Total Operating Expenses	945.6M	881.6M	1.1B	1.1B	438.6M	809.7M
Income Before Tax	94.1M	218.7M	273.2M	348.1M	298.7M	313.6M
Total Other Income Expense Net	20.1M	30.9M	21.0M	9.2M	84.7M	88.9M
Net Income	78.7M	170.6M	188.6M	267.2M	224.6M	235.9M
Income Tax Expense	15.4M	48.1M	77.3M	80.9M	74.1M	77.8M
Selling General Administrative	9.0M	40.7M	101.7M	57.6M	38.1M	72.9M
Selling And Marketing Expenses	178.4M	129.9M	153.2M	186.1M	163.4M	136.6M
Research Development	3.7M	1.2M	1.5M	3.5M	3.1M	3.2M
Net Income From Continuing Ops	78.7M	170.6M	195.9M	267.2M	224.6M	235.9M
Net Income Applicable To Common Shares	78.7M	170.6M	195.9M	267.2M	307.3M	322.7M
Tax Provision	15.4M	48.1M	77.3M	80.9M	74.1M	38.7M
Interest Income	3.8M	5.1M	2.9M	4.1M	3.7M	3.5M
Net Interest Income	16.5M	(5.1M)	(2.9M)	(4.1M)	(8.1M)	(7.7M)
Reconciled Depreciation	11.3M	10.9M	15.3M	12.1M	16.6M	13.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in Jagsonpal Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jagsonpal Historical Income Statement

About Jagsonpal Income Statement Analysis

Jagsonpal Pharmaceuticals Income Statement Chart

Depreciation And Amortization

Interest Expense

Total Revenue

Gross Profit

Other Operating Expenses

Net Income Applicable To Common Shares

Jagsonpal Pharmaceuticals income statement Correlations

Jagsonpal Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jagsonpal Pharmaceuticals income statement Accounts

Also Currently Popular

Other Information on Investing in Jagsonpal Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Other Operating Expenses	+ 0.99	Total Revenue
Net Income From Continuing Ops	+ 0.99	Income Before Tax
Net Income From Continuing Ops	+ 0.99	Net Income
Ebit	+ 0.98	Operating Income

Net Interest Income	- 0.87	Interest Income
Net Interest Income	- 0.86	Interest Expense
Selling And Marketing Expenses	- 0.85	Interest Expense
Net Interest Income	- 0.84	Research Development
Research Development	- 0.84	Selling And Marketing Expenses
Interest Income	- 0.8	Selling And Marketing Expenses